BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, Rizvi AA, Cosentino F. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis 2018;1864:2814-21. [PMID: 29778663 DOI: 10.1016/j.bbadis.2018.05.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Vekic J, Vujcic S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, Stoian AP, Zeljkovic A, Rizzo M. The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites 2023;13. [PMID: 36677002 DOI: 10.3390/metabo13010077] [Reference Citation Analysis]
2 Giglio RV, Papanas N, Rizvi AA, Ciaccio M, Patti AM, Ilias I, Pantea Stoian A, Sahebkar A, Janez A, Rizzo M. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Kaunas) 2022;58:1475. [PMID: 36295635 DOI: 10.3390/medicina58101475] [Reference Citation Analysis]
3 Manosroi W, Phudphong P, Atthakomol P, Phimphilai M. The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01135-y] [Reference Citation Analysis]
4 Rizzo M, Cosentino F, Mantzoros C. Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes. Expert Rev Clin Pharmacol 2022;:1-3. [PMID: 35924858 DOI: 10.1080/17512433.2022.2108400] [Reference Citation Analysis]
5 Vekic J, Silva-nunes J, Rizzo M. Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment. Metabolites 2022;12:712. [DOI: 10.3390/metabo12080712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Janez A, Muzurovic E, Stoian AP, Haluzik M, Guja C, Czupryniak L, Duvnjak L, Lalic N, Tankova T, Bogdanski P, Papanas N, Nunes JS, Kempler P, Fras Z, Rizzo M. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol 2022:S0167-5273(22)01085-3. [PMID: 35905827 DOI: 10.1016/j.ijcard.2022.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Khalimov YS, Agafonov PV, Kireeva EB. Obesity and COVID-19: insights from two pandemics. jour 2022;14:27-38. [DOI: 10.22625/2072-6732-2022-14-2-27-38] [Reference Citation Analysis]
8 Lin L, Tan W, Pan X, Tian E, Wu Z, Yang J. Metabolic Syndrome-Related Kidney Injury: A Review and Update. Front Endocrinol 2022;13:904001. [DOI: 10.3389/fendo.2022.904001] [Reference Citation Analysis]
9 Costanzo G, Frasca F. Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico. L'Endocrinologo 2022;23:258-262. [DOI: 10.1007/s40619-022-01064-x] [Reference Citation Analysis]
10 Wang C, Chen J, Wang P, Qing S, Li W, Lu J. Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis. Front Endocrinol 2022;13:821028. [DOI: 10.3389/fendo.2022.821028] [Reference Citation Analysis]
11 Premji R, Nylen ES, Naser N, Gandhi S, Burman KD, Sen S. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. Metab Syndr Relat Disord 2022. [PMID: 35452324 DOI: 10.1089/met.2022.0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Parilli-moser I, Hurtado-barroso S, Guasch-ferré M, Lamuela-raventós RM. Effect of Peanut Consumption on Cardiovascular Risk Factors: A Randomized Clinical Trial and Meta-Analysis. Front Nutr 2022;9:853378. [DOI: 10.3389/fnut.2022.853378] [Reference Citation Analysis]
13 Janić M, Rizzo M, Cosentino F, Pantea Stoian A, Lunder M, Šabović M, Janež A. Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Ther 2022;13:795-810. [PMID: 35258841 DOI: 10.1007/s13300-022-01226-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Magán-Fernández A, Citarrella R, Papanas N, Janez A, Stoian AP, Rizvi AA, Rizzo M. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. Diabetes Ther 2022;13:453-64. [PMID: 35167051 DOI: 10.1007/s13300-022-01217-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Rizvi AA, Linhart A, Vrablik M, Liberopoulos E, Rizzo M. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf 2022;:1-3. [PMID: 35188012 DOI: 10.1080/14740338.2022.2043848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Vekic J, Zeljkovic A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina 2022;58:299. [DOI: 10.3390/medicina58020299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-nunes J, Stoian AP, Rizzo M. A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. Metabolites 2022;12:108. [DOI: 10.3390/metabo12020108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
18 Popoviciu MS, Marin VN, Vesa CM, Stefan SD, Stoica RA, Serafinceanu C, Merlo EM, Rizvi AA, Rizzo M, Busnatu S, Stoian AP. Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study. Healthcare 2022;10:174. [DOI: 10.3390/healthcare10010174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
19 Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci 2022;23:786. [PMID: 35054972 DOI: 10.3390/ijms23020786] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 65.0] [Reference Citation Analysis]
20 Busnatu SS, Salmen T, Pana MA, Rizzo M, Stallone T, Papanas N, Popovic D, Tanasescu D, Serban D, Stoian AP. The Role of Fructose as a Cardiovascular Risk Factor: An Update. Metabolites 2022;12:67. [PMID: 35050189 DOI: 10.3390/metabo12010067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
21 Patti AM, Giglio RV, Papanas N, Serban D, Stoian AP, Pafili K, Al Rasadi K, Rajagopalan K, Rizvi AA, Ciaccio M, Rizzo M. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina (Kaunas) 2022;58:109. [PMID: 35056417 DOI: 10.3390/medicina58010109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zarkasi KA, Abdul Murad NA, Ahmad N, Jamal R, Abdullah N. Coronary Heart Disease in Type 2 Diabetes Mellitus: Genetic Factors and Their Mechanisms, Gene-Gene, and Gene-Environment Interactions in the Asian Populations. Int J Environ Res Public Health 2022;19:647. [PMID: 35055468 DOI: 10.3390/ijerph19020647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
23 Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, Mantzoros CS. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. J Cardiovasc Pharmacol Ther 2022;27:10742484221146371. [PMID: 36546652 DOI: 10.1177/10742484221146371] [Reference Citation Analysis]
24 Escobar C, Castro A, Gómez Cerezo JF, Luis Górriz J, Obaya Rebollar JC, Villar-taibo R. Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2. Revista Española de Cardiología Suplementos 2022;22:1-9. [DOI: 10.1016/s1131-3587(22)00013-9] [Reference Citation Analysis]
25 Stoian AP, Kempler P, Stulnig T, Rizvi AA, Rizzo M. Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. Metab Syndr Relat Disord 2021. [PMID: 34967689 DOI: 10.1089/met.2021.0133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Rizzo M. Molecular Endocrinology and Metabolism in 2021: What's New. Int J Mol Sci 2021;22:13375. [PMID: 34948171 DOI: 10.3390/ijms222413375] [Reference Citation Analysis]
27 Reshad RAI, Riana SH, Chowdhury MA, Moin AT, Miah F, Sarkar B, Jewel NA. Diabetes in COVID-19 patients: challenges and possible management strategies. Egypt J Bronchol 2021;15. [DOI: 10.1186/s43168-021-00099-2] [Reference Citation Analysis]
28 Bonilha I, Hajduch E, Luchiari B, Nadruz W, Le Goff W, Sposito AC. The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. Metabolites 2021;11:807. [PMID: 34940565 DOI: 10.3390/metabo11120807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Vekic J, Zeljkovic A, Stefanovic A, Giglio RV, Ciaccio M, Rizzo M. Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents. Int J Mol Sci 2021;22:12409. [PMID: 34830295 DOI: 10.3390/ijms222212409] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Rizvi AA, Janez A, Rizzo M. Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. Int J Mol Sci 2021;22:12311. [PMID: 34830193 DOI: 10.3390/ijms222212311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Ionescu M, Stoian AP, Rizzo M, Serban D, Nuzzo D, Mazilu L, Suceveanu AI, Dascalu AM, Parepa IR. The Role of Endothelium in COVID-19. Int J Mol Sci 2021;22:11920. [PMID: 34769350 DOI: 10.3390/ijms222111920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
32 Rizvi AA, Stoian AP, Janez A, Rizzo M. Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. Biomedicines 2021;9:1579. [PMID: 34829807 DOI: 10.3390/biomedicines9111579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
33 Mahadzir MDA, Quek KF, Ramadas A. Group-Based Lifestyle Intervention Strategies for Metabolic Syndrome: A Scoping Review and Strategic Framework for Future Research. Medicina (Kaunas) 2021;57:1169. [PMID: 34833387 DOI: 10.3390/medicina57111169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Popovic DS, Papanas N, Pantea Stoian A, Rizvi AA, Janez A, Rizzo M. Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. Diabetes Ther 2021;12:3037-54. [PMID: 34699021 DOI: 10.1007/s13300-021-01170-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
35 Banerjee Y, Pantea Stoian A, Cicero AFG, Fogacci F, Nikolic D, Sachinidis A, Rizvi AA, Janez A, Rizzo M. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf 2021;:1-12. [PMID: 34596005 DOI: 10.1080/14740338.2022.1988568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
36 Zobel EH, Ripa RS, von Scholten BJ, Rotbain Curovic V, Kjaer A, Hansen TW, Rossing P, Størling J. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Sci Rep 2021;11:18522. [PMID: 34535716 DOI: 10.1038/s41598-021-97967-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
37 Xiao S, Yang Y, Liu Y, Zhu J. Liraglutide may affect visceral fat accumulation in diabetic rats via changes in FTO, AMPK, and AKT expression. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-021-00974-0] [Reference Citation Analysis]
38 Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne) 2021;12:721135. [PMID: 34497589 DOI: 10.3389/fendo.2021.721135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
39 Banerjee Y, Pantea Stoian A, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, Rizzo M. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf 2021;20:1309-15. [PMID: 34424130 DOI: 10.1080/14740338.2021.1970744] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, Lakshmanan M, Mellbin L, Probstfield J, Riddle MC, Shaw JE, Avezum A, Basile JN, Cushman WC, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pais P, Pīrāgs V, Pogosova N, Raubenheimer PJ, Sheu WH, Rydén L. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 2021;42:2565-73. [PMID: 33197271 DOI: 10.1093/eurheartj/ehaa777] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
41 Sarkar S, Das D, Borsingh Wann S, Kalita J, Manna P. Is diabetes mellitus a wrongdoer to COVID-19 severity? Diabetes Res Clin Pract 2021;178:108936. [PMID: 34217771 DOI: 10.1016/j.diabres.2021.108936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wen S, Nguyen T, Gong M, Yuan X, Wang C, Jin J, Zhou L. An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). Diabetes Metab Syndr Obes 2021;14:2955-72. [PMID: 34234493 DOI: 10.2147/DMSO.S312527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Berberich AJ, Hegele RA. Lipid effects of glucagon-like peptide 1 receptor analogs. Curr Opin Lipidol 2021;32:191-9. [PMID: 33900276 DOI: 10.1097/MOL.0000000000000750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
44 Uneda K, Kawai Y, Yamada T, Kinguchi S, Azushima K, Kanaoka T, Toya Y, Wakui H, Tamura K. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients. Sci Rep 2021;11:10166. [PMID: 33986377 DOI: 10.1038/s41598-021-89620-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Giglio RV, Pantea Stoian A, Al-Rasadi K, Banach M, Patti AM, Ciaccio M, Rizvi AA, Rizzo M. Novel Therapeutical Approaches to Managing Atherosclerotic Risk. Int J Mol Sci 2021;22:4633. [PMID: 33924893 DOI: 10.3390/ijms22094633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
46 Tsymbaliuk V, Tronko M, Antypkin Y, Kushnirenko S, Popova V. Diabetes mellitus in combination with COVID-19: modern views on therapy. RE 2021. [DOI: 10.18370/2309-4117.2021.57.8-20] [Reference Citation Analysis]
47 Marrano N, Biondi G, Borrelli A, Cignarelli A, Perrini S, Laviola L, Giorgino F, Natalicchio A. Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity. Biomolecules 2021;11:286. [PMID: 33671882 DOI: 10.3390/biom11020286] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
48 Michałowska J, Miller-Kasprzak E, Bogdański P. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 2021;13:351. [PMID: 33503878 DOI: 10.3390/nu13020351] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
49 Yang J, Le Y, Wei T, Wang K, Yang K, Xiao W, Hong T, Wei R. Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes. J Diabetes Complications 2021;35:107797. [PMID: 33293208 DOI: 10.1016/j.jdiacomp.2020.107797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Giglio RV, Nikolic D, Volti GL, Stoian AP, Banerjee Y, Magan-Fernandez A, Castellino G, Patti AM, Chianetta R, Castracani CC, Montalto G, Rizvi AA, Sesti G, Rizzo M. Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. Metabolites 2020;10:E391. [PMID: 33008044 DOI: 10.3390/metabo10100391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, Duffin KL, Taskinen MR, Ruotolo G. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab 2020;22:2451-9. [PMID: 33462955 DOI: 10.1111/dom.14174] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
52 Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. Biochem Pharmacol 2020;180:114187. [PMID: 32755557 DOI: 10.1016/j.bcp.2020.114187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
53 Papazafiropoulou AK, Antonopoulos S. The COVID-19 pandemic and diabetes mellitus. Arch Med Sci Atheroscler Dis 2020;5:e200-5. [PMID: 32832721 DOI: 10.5114/amsad.2020.97435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Koliaki C, Tentolouris A, Eleftheriadou I, Melidonis A, Dimitriadis G, Tentolouris N. Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns. J Clin Med 2020;9:E2288. [PMID: 32708504 DOI: 10.3390/jcm9072288] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
55 Stoian AP, Papanas N, Prazny M, Rizvi AA, Rizzo M. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther 2020;25:494-6. [DOI: 10.1177/1074248420937868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
56 Zhou R, Duncan K, Lopez J, Rich K, Swislocki A. Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced. Metab Syndr Relat Disord 2020;18:321-7. [PMID: 32580677 DOI: 10.1089/met.2019.0122] [Reference Citation Analysis]
57 Vecchié A, Montecucco F, Carbone F, Dallegri F, Bonaventura A. Diabetes and Vascular Disease: Is It All About Glycemia? Curr Pharm Des 2019;25:3112-27. [PMID: 31470783 DOI: 10.2174/1381612825666190830181944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
58 Cuschieri S, Grech S. COVID-19 and diabetes: The why, the what and the how. J Diabetes Complications 2020;34:107637. [PMID: 32456846 DOI: 10.1016/j.jdiacomp.2020.107637] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 22.0] [Reference Citation Analysis]
59 Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: What should be considered? Diabetes Res Clin Pract 2020;163:108151. [PMID: 32305399 DOI: 10.1016/j.diabres.2020.108151] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 23.3] [Reference Citation Analysis]
60 Xia J, Li Q, Liu Y, Ren Q, Gao J, Tian Y, Li J, Zhang B, Sun H, Liu S. A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine. Front Pharmacol 2020;11:372. [PMID: 32273846 DOI: 10.3389/fphar.2020.00372] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
61 Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. J Clin Med 2020;9:E912. [PMID: 32225082 DOI: 10.3390/jcm9040912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
62 Cӑtoi AF, Vodnar DC, Corina A, Nikolic D, Citarrella R, Pérez-Martínez P, Rizzo M. Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives. Curr Pharm Des 2019;25:2038-50. [PMID: 31298152 DOI: 10.2174/1381612825666190708190437] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
63 Giorgino F, Caruso I, Moellmann J, Lehrke M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 2020;104:154045. [PMID: 31821814 DOI: 10.1016/j.metabol.2019.154045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
64 Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjöström CD, Ruggles JA, Hernandez AF, Buse JB, Mentz RJ, Holman RR. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol 2019;18:138. [PMID: 31640705 DOI: 10.1186/s12933-019-0942-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
65 Han F, Hou N, Liu Y, Huang N, Pan R, Zhang X, Mao E, Sun X. Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice. Biomed Pharmacother 2019;120:109537. [PMID: 31605951 DOI: 10.1016/j.biopha.2019.109537] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
66 Schwarz PEH, Timpel P, Harst L, Greaves CJ, Ali MK, Lambert J, Weber MB, Almedawar MM, Morawietz H. Reprint of: Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:3071-86. [PMID: 30522637 DOI: 10.1016/j.jacc.2018.10.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Schwarz PEH, Timpel P, Harst L, Greaves CJ, Ali MK, Lambert J, Weber MB, Almedawar MM, Morawietz H. Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:1829-44. [PMID: 30286928 DOI: 10.1016/j.jacc.2018.07.081] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
68 Mannina C, Jin Z, Russo C, Homma S, Elkind MS, Rundek T, Lee TC, Matsumoto K, Shames S, Sacco RL, Tullio MRD. Effect of hypertension and diabetes on subclinical left ventricular systolic dysfunction in a predominantly elderly population-based cohort. Eur J Prev Cardiol 2020;27:2173-5. [PMID: 31446789 DOI: 10.1177/2047487319872571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
69 Caruso I, Cignarelli A, Giorgino F. Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. Trends Endocrinol Metab 2019;30:578-89. [PMID: 31401015 DOI: 10.1016/j.tem.2019.07.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
70 Russo GT, Giandalia A, Cucinotta D. GLP-1: soltanto la glicemia? L'Endocrinologo 2019;20:66-71. [DOI: 10.1007/s40619-019-00537-w] [Reference Citation Analysis]
71 Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. J Intern Med 2019;286:16-31. [PMID: 30888088 DOI: 10.1111/joim.12890] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
72 DiNicolantonio JJ, McCarty M, OKeefe J. Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. Open Heart 2019;6:e000890. [PMID: 30997120 DOI: 10.1136/openhrt-2018-000890] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
73 Cianflone D, Rizvi AA, Rizzo M. Microvascular and macrovascular effects of liraglutide. Int J Cardiol 2019;286:17-8. [PMID: 30878237 DOI: 10.1016/j.ijcard.2019.02.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Patti AM, Giglio RV, Papanas N, Rizzo M, Rizvi AA. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol 2019;12:129-43. [PMID: 30644763 DOI: 10.1080/17512433.2019.1567328] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
75 Mesa F, Magan-Fernandez A, Castellino G, Chianetta R, Nibali L, Rizzo M. Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives. Biochim Biophys Acta Mol Basis Dis 2019;1865:476-84. [PMID: 30529255 DOI: 10.1016/j.bbadis.2018.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
76 Martín-timón I, Sevillano-collantes C, García-domínguez M, Marín-peñalver JJ, Ugalde-abiega B, del Cañizo-gómez FJ. Update on the Management of Diabetic Dyslipidaemia. EMJ Diabet 2018. [DOI: 10.33590/emjdiabet/10312768] [Reference Citation Analysis]
77 Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519-1529. [PMID: 30291013 DOI: 10.1016/s0140-6736(18)32261-x] [Cited by in Crossref: 864] [Cited by in F6Publishing: 896] [Article Influence: 172.8] [Reference Citation Analysis]